Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Transcript
What will be the biggest takeaways from this year’s ASH meeting?
I’m very focused on the on the myeloma sessions today. And I think on the Janssen side, right, we’ve been innovating in the myeloma space for the last 15 years. We have 4 different compounds in the multiple myeloma space being reported on at ASH. We have daratumumab, we have our CAR T cilta-cel, or JNJ-4528. We’re extremely excited to be presenting the first results from our bispecific antibody called talquetamab, which targets GPRC5D. And as a T-cell redirector, these are the first results from that phase 1 study. And then we also reporting updated data from a similar phase 1 study with teclistamab, which is our BCMAxCD3 for multiple myeloma.
You need to build regimens to really advance care for patients. Teclistamab, talquetamab, cilta-cel, daratumumab, we believe that these are all important components to build regimens to get patients towards the ultimate goal of hopefully trying to eradicate disease and get meaningful cure. We’re excited about talquetamab. We’ve reached a recommended phase 2 dose; it seems to be highly efficacious in patients who are triple refractory and run out of options; similarly, teclistamab; similarly, cilta-cel.
So for me, I’m really excited to see the reaction of the medical community about the multiple myeloma data that we’re bringing forward, and we’re already seeing excitement from that. We saw Vincent Rajkumar [S. Vincent Rajkumar, MD, Mayo Clinic] already tweeting out that the talquetamab abstract is his No. 1 favorite for ASH. So tip my hat to Vincent Rajkumar with that. We’re excited about it, too, and I think that we’re on the cusp of continuing to look toward bringing forward new therapies that can really advance care for patients.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More